The National Institute of Allergy and Infectious Disease (NIAID) will provide the $3.3m grant spread over for four years.
Trellis president and CEO Stote Ellsworth said Trellis has deployed its CellSpot technology to discover four superlative antibodies targeting high-impact infectious diseases, including CMV, RSV and Group 1 and Group 2 Influenza.
"This substantial SBIR funding provides validation of the strength of our program and allows us to advance our CMV product candidate towards human clinical testing, building value and reducing risk," Ellsworth added.
”By staying focused on rare antibody discovery and preclinical development, we stick with what we do best.”
CMV345 is intended to neutralize transmission of CMV to the fetus in pregnant women.
CMV is a virus that may get transmitted to a developing child before birth, which causes primary CMV and recurrent CMV infections.